Trial Profile
Effect of Empagliflozin on Cardiac Output in Patients With Acute Heart Failure (EMPA Acute Heart Failure)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Acute heart failure
- Focus Therapeutic Use
- 09 Mar 2021 Status changed from recruiting to discontinued due to COVID-19.
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.
- 19 Jun 2018 New trial record